CalciMedica says cash sufficient to fund operating plan into mid-2026

Cash, cash equivalents, and short-term investments were $18.7M as of December 31, 2024, which, combined with the net proceeds of $9.7M from the company’s recent debt financing announced in March 2025, the company expects to be sufficient to fund its current operating plan into mid-2026. “Enrollment in our Phase 2 KOURAGE trial is on track to deliver data around the end of 2025,” said Rachel Leheny, Ph.D., CEO of CalciMedica (CALC). “Looking ahead to the KOURAGE readout, we are further encouraged by the promising readthrough from the data recently presented at the 30th International AKI & CRRT Conference, which show a 62.7% relative reduction in mortality in CARDEA patients with both kidney failure and respiratory failure, mirroring KOURAGE’s patient population. With the proceeds from our recent credit facility with Avenue Capital, we have ample runway to get through our KOURAGE data readout based on our current enrollment projections and engage with the FDA on the design of a Phase 3 program in acute pancreatitis with SIRS in the next few months.”